ANTX AN2 THERAPEUTICS INC

AN2 Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

MENLO PARK, Calif.--(BUSINESS WIRE)--

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will present at the H.C. Wainwright 26th Annual Global Investment Conference.

Details of the event is as follows:

H.C. Wainwright 26th Annual Global Investment Conference

  • Eric Easom, Co-Founder, Chairman, President and CEO will provide a corporate overview on Tuesday, September 10 at 9:30am ET

A webcast of the presentation can be accessed on the Investors section of the AN2 Therapeutics website at . An archived replay will be available for at least 30 days following the presentation.

About AN2 Therapeutics, Inc.

AN2 Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. AN2 has a pipeline of boron-based compounds in development for Chagas disease, nontuberculous mycobacteria (NTM), and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. For more information, please visit our website at .

EN
28/08/2024

Underlying

ANTXAN2 THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AN2 THERAPEUTICS INC

 PRESS RELEASE
Free
ANTX AN2 THERAPEUTIC...

AN2 Therapeutics to Present at the H.C. Wainwright 26th Annual Global ...

MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will present at the H.C. Wainwright 26th Annual Global Investment Conference. Details of the event is as follows: H.C. Wainwright 26th Annual Global Investment Conference Eric Easom, Co-Founder, Chairman, President and CEO will provide a corporate overview on Tuesday, September 10 at 9:30am ET A ...

August 28, 2024 1 EN
 PRESS RELEASE
Free
ANTX AN2 THERAPEUTIC...

AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan

MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that it has adopted a limited duration stockholder rights plan, which is scheduled to expire on August 15, 2025. The Company recently became aware of the rapid accumulation of a significant amount (19.3%) of the common stock of the Company by BML Investment Partners, L.P. (BML), as disclosed in a Schedule 13G/A filed with the U.S. Securities and Exchange Commi...

August 16, 2024 1 EN
 PRESS RELEASE
Free
ANTX AN2 THERAPEUTIC...

AN2 Therapeutics Reports Second Quarter 2024 Financial Results and Rec...

MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform today reported financial results for the quarter ended June 30, 2024. “We reported results from the EBO-301 Phase 2/3 study in patients with treatment-refractory MAC lung disease last week and over the coming months will further analyze the data to determine next steps in NTM lung disease,” said Eric Easom, Co-Founder, Chairman, President and CEO. “Despite this setback, we rem...

August 13, 2024 1 EN
 PRESS RELEASE
Free
ANTX AN2 THERAPEUTIC...

AN2 Therapeutics Provides Update on EBO-301 Phase 2/3 Study Evaluating...

MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform today announced topline results from the Phase 2 part of the EBO-301 Phase 2/3 study evaluating epetraborole on top of an optimized background regimen (OBR) in treatment-refractory MAC lung disease. The Phase 2 part of the study met its primary objective of demonstrating the potential validation of a novel patient-reported outcome (PRO) tool and a higher PRO-based clinical res...

August 8, 2024 1 EN
 PRESS RELEASE
Free
ANTX AN2 THERAPEUTIC...

AN2 Therapeutics Reports First Quarter 2024 Financial Results and Rece...

MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the quarter ended March 31, 2024. “The Phase 2 topline data, expected to be available in August, will include the first clinical efficacy data for epetraborole in patients with treatment-refractory MAC. The patients enrolled in EBO-301 are highly refractory with limited to no treatment options; and background regimens available prov...

May 14, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch